Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
NxStage Medical, Inc. (NXTM)
|
Add to portfolio |
|
|
|
| Price: |
$30.00
| | Metrics |
| OS: |
66.7
|
M
| |
-2
|
% ROE
|
| Market cap: |
$2
|
B
| |
-2
|
% ROIC
|
|
Net cash:
|
$81.4
|
M
| |
$1.22
|
per share
|
|
EV:
|
$1.92
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$31.3
|
M
| |
61.4
|
x EV/EBITDA
|
|
EBIT
|
($2.8)
|
M
| |
|
|
| EPS |
($0.08)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 |
| Revenues | 395.4 | 365.1 | 334.7 | 301.5 | 263.4 | 246.4 | 217.3 | 179.2 |
| Revenue growth | 8.3% | 9.1% | 11.0% | 14.5% | 6.9% | 13.4% | 21.2% | 20.5% |
| Cost of goods sold | 258.1 | 243.0 | 230.9 | 185.6 | 160.9 | 149.3 | 139.6 | 121.1 |
| Gross profit | 137.2 | 122.1 | 103.8 | 115.9 | 102.5 | 97.1 | 77.6 | 58.1 |
| Gross margin | 34.7% | 33.5% | 31.0% | 38.4% | 38.9% | 39.4% | 35.7% | 32.4% |
| Sales and marketing | 68.2 | 63.9 | 58.5 | 55.4 | 47.8 | 40.5 | 37.6 | 34.2 |
| Research and development | 39.6 | 31.0 | 26.2 | 22.6 | 18.9 | 17.1 | | 12.9 |
| General and administrative | 41.8 | 32.8 | 35.1 | 34.1 | 32.3 | 27.5 | | 22.8 |
| EBITA | -11.9 | -2.3 | -12.0 | -19.4 | -15.0 | -8.4 | -22.7 | -23.7 |
| EBITA margin | -3.0% | -0.6% | -3.6% | -6.4% | -5.7% | -3.4% | -10.5% | -13.2% |
| Amortization of intangibles | 2.0 | 2.0 | 2.6 | 2.8 | 2.8 | 2.8 | 2.8 | 2.8 |
| EBIT | -13.9 | -4.3 | -14.6 | -22.2 | -17.8 | -11.2 | -25.5 | -26.5 |
| EBIT margin | -3.5% | -1.2% | -4.4% | -7.4% | -6.8% | -4.5% | -11.7% | -14.8% |
| Pre-tax income | -15.5 | -6.2 | -15.2 | -23.1 | -18.8 | -14.1 | -20.5 | -30.9 |
| Income taxes | -0.1 | 1.1 | 1.1 | 1.3 | -0.2 | 1.0 | 0.9 | 0.8 |
| Tax rate | 0.9% | | | | 1.3% | | | |
| Net income | -14.5 | -4.8 | -15.3 | -23.9 | -18.6 | -15.2 | 0.0 | -31.7 |
| Net margin | -3.7% | -1.3% | -4.6% | -7.9% | -7.0% | -6.1% | 0.0% | -17.7% |
| |
| Diluted EPS | ($0.22) | ($0.07) | ($0.24) | ($0.39) | ($0.31) | ($0.26) | $0.00 | ($0.66) |
| Shares outstanding (diluted) | 65.9 | 64.5 | 63.4 | 61.7 | 60.3 | 57.9 | 54.2 | 48.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|